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A B S T R A C T   
The therapeutic precision and clinical applicability of drug-eluting coatings can be substantially improved by 
facilitating tunable drug delivery. However, the design of coatings which allows for precise control over drug 
release kinetics is still a major challenge. Here, a double-layered silk fibroin (SF) coating system was constructed 
by sequential electrophoretic deposition. A mixture of dissolved Bombyx mori SF (bmSF) molecules and pre-made 
bmSF nanospheres at different ratios was deposited as under-layer. Subsequently, this underlayer was covered by 
a top-layer comprising Antheraea pernyi SF (apSF) molecules (rich in arginylglycylaspartic acid, RGD) to improve 
the cellular response of the resulting double-layered coatings. Additionally, model drug doxycycline was either 
pre-mixed with dissolved bmSF molecules or pre-loaded into pre-made bmSF nanospheres at the same amount 
before their mixing and deposition. The thickness and nanosphere content of the under-layer architecture were 
proportional to the deposition time and nanosphere concentration in precursor mixtures, respectively. The 
surface topography, wettability, degradation rate and adhesion strength were comparable within the double- 
layered coating system. As expected, RGD-rich apSF top-layer improved cell adhesion, spreading and prolifer-
ation compared with bmSF top-layer. Furthermore, the amount and duration of drug release increased linearly 
with increasing nanosphere concentration at fixed deposition time, whereas drug release amount increased 
linearly with increasing deposition time. These results indicate that the dosage and kinetics of loaded drugs can 
be quantitatively tailored by altering nanosphere concentration and deposition time as main processing pa-
rameters. Overall, this study illustrates the strong potential of pre-defining coating architecture to facilitate 
control over drug delivery.   
1. Introduction 
Coatings on medical device surfaces, such as drug-eluting stents [1, 
2], external fixators [3,4] and implants [5,6], are considered as an 
effective strategy to act as reservoir for the local release of therapeutic 
agents. Obviously, the required release duration and dosage of a specific 
drug can vary among different clinical scenarios. For example, to pre-
vent infection, antibiotic-loaded coatings deposited on orthopedic fixa-
tion devices for open fracture patients usually require sustained drug 
delivery at high dosages [7,8]. However, antibiotic delivery at insuffi-
cient amounts and/or duration may result in clinical complications such 
as limited prophylactic efficacy or antibiotic resistance [8]. Therefore, 
precise control over the amount and kinetics of local antibiotic delivery 
will improve therapeutic precision and expand the clinical applicability 
of drug-eluting coatings [9]. 
Electrophoretic deposition (EPD) is one of the most attractive tech-
niques to produce coatings for biomedical applications due to advan-
tages such as: i) deposition in mild aqueous environments at room 
temperature [10]; ii) fabrication of homogeneous and conformal coat-
ings on complex or porous medical devices [11]; iii) tight control over 
coating properties via processing parameters [12]; and iv) compatibility 
for industrial upscaling due to the relatively simple equipment and short 
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fabrication time [13]. Previously, drugs (e.g. antibiotics) have been 
mixed with EPD coating precursors before their co-deposition [11,12] or 
post-loaded via adsorption [14]. However, these drug loading strategies 
offer poor control over drug delivery. More recently, several approaches 
have been employed to overcome this limitation, such as regulation of 
the degradation rate of the coating matrix [15], cross-linking of the drug 
with the coating matrix [16], and adding drug delivery microcarriers 
into the coating matrix [6,13,17,18]. However, these modified coating 
systems still suffer from several shortcomings. For example, excessively 
fast coating degradation may compromise the cytocompatibility of the 
coating [15,19]. Moreover, the use of an additional crosslinker [16] or 
coating components (e.g. metal-organic frameworks [6], carbon nano-
tube [13], and graphene oxide sheets [18]) may raise concerns 
regarding biosafety and manufacturing costs. 
Therefore, we and other groups reported that silk fibroin (SF) coat-
ings can be deposited in a simple and straightforward manner by using 
dissolved Bombyx mori SF (bmSF) molecules [11,12,20–22] or pre-made 
bmSF nanospheres as precursor components [23]. The EPD coating 
comprising bmSF nanospheres was able to decelerate the release of 
entrapped drugs considerably as compared to monolithic coatings 
composed of bmSF molecules [23]. Nevertheless, drug release kinetics 
could not yet be tuned to desire. In the current study, we aimed to 
proceed with the optimization of EPD-deposited SF coatings and hy-
pothesized that tunable drug release kinetics can be obtained by 
depositing coatings composed of both bmSF molecules and bmSF nano-
spheres at different ratios. 
bmSF has recently attracted attention for biomacromolecule delivery 
due to its stabilizing effect on sensitive biological compounds (e.g. anti-
biotics) [24] and its hypoallergenicity [25,26]. However, bmSF molecules 
do not contain cell recognition motifs, such as arginylglycylaspartic acid 
(RGD), which facilitates cell adhesion and spreading. On the other hand, 
Antheraea pernyi SF (apSF), an alternative silk protein, is rich in such RGD 
sequences. In view of the high costs of apSF, we propose the deposition of 
apSF molecules as top-layer onto a bmSF under-layer as a cost-effective way 
to favor the cellular response to an SF-coated device without comprising 
the beneficial properties of bmSF. 
In this study, a novel double-layered SF coating system was prepared 
by sequential EPD. First, a mixture of dissolved bmSF molecules and pre- 
made bmSF nanospheres at different ratios was deposited as under-layer 
to enable tunable drug delivery. Subsequently, a top-layer comprising 
apSF molecules was deposited to further improve the cellular response to 
the coating. To investigate the deposition mechanism of coatings, the 
colloidal stability of EPD solutions/suspensions was studied as a func-
tion of pH. Subsequently, we studied the influence of deposition time 
and concentration of nanospheres in precursor mixtures on the thickness 
and nanosphere content of the under-layer architectures. Moreover, the 
surface topography, wettability, degradation, adhesion strength and 
cytocompatibility of the coating system were characterized. Further-
more, doxycycline, a broad-spectrum antibiotic, was selected as model 
drug to investigate the relationship between coating processing pa-
rameters, coating architecture and drug delivery performance. 
2. Materials and methods 
2.1. Preparation of bmSFsol, apSFsol, and bmSFsus 
Aqueous solutions of bmSF (bmSFsol) or apSF molecules (apSFsol) 
were prepared as previously reported [11,27]. Briefly, Bombyx mori and 
Antheraea pernyi silk cocoons, both provided by the State Key Laboratory 
of Silkworm Genome Biology of Southwest University, China, were first 
boiled in 0.02 M Na2CO3 aqueous solution for 30 min and washed with 
water for 1 h to remove sericin. After drying, the degummed Bombyx 
mori silk fibers were dissolved in 9.3 M LiBr aqueous solution at 1:4 
(w/v) bath ratio for 4 h at 60 ◦C [11]. The degummed Antheraea pernyi 
silk fibers were dissolved in melted Ca(NO3)2⋅4H2O at bath ratio w/v: 
1:10 at 105 ◦C for 5 h [27]. Subsequently, the protein solutions were 
dialyzed against water using a 3500 Da cut-off dialysis membrane for 72 
h to remove salts. Insoluble residues were removed by centrifugation at 
5000 rpm (Universal 32R, Hettich, Germany) for 1h. The final protein 
concentration in bmSFsol and apSFsol was 8 wt % and 2.5 wt% measured 
by dry weighing, respectively. 
The aqueous suspension of bmSF nanospheres (bmSFsus) was pre-
pared using a previously described precipitation approach [23]. To this 
end, bmSFsol (5 wt %) was added dropwise into acetone to form bmSF 
nanospheres. The bmSF nanospheres were washed with water and 
centrifuged at 10000 rpm (9391 rcf), (Centrifuge 5415r, Eppendorf, 
Germany) for three times to remove acetone. A sonicator (UP50H, 
Hielscher, Germany) was used to ultrasonically disperse bmSFsus in an 
ice bath for 30 s (50% amplitude) before use. 
2.2. Drug pre-loading into bmSF nanospheres in bmSFsus and pre-mixing 
drug with bmSF molecules in bmSFsol 
The model drug doxycycline hyclate (D9891, Sigma, Germany) was 
either pre-loaded into bmSF nanospheres (bmSFsus) or pre-mixed with 
bmSF molecules (bmSFsol) at the same amount. 
To obtain drug loaded bmSF nanospheres, doxycycline solution was 
dropped into bmSFsol (5 wt %) under stirring (100 rpm) at different 
doxycycline/SF weight ratios of 0.05, 0.10, 0.15, 0.20, 0.25 or 0.30. 
Then, the various solutions were added dropwise into acetone to pre-
cipitate doxycycline-loaded bmSF nanospheres [23]. Acetone did not to 
compromise the pharmaceutical activity of doxycycline [28,29]. These 
drug-loaded nanospheres were washed with water and centrifuged at 
10000 rpm (9391 rcf) for 5 min for three times to remove any residual 
acetone and unloaded doxycycline. 
High performance liquid chromatography (HPLC, BioTek, synergy 
HTX, USA) at 360 nm was used to measure the amount of unbound 
doxycycline in the washed supernatants with a LiChrospher RP-18 end 
capped HPLC column (125 mm × 4 mm, particle size 5 μm), as previ-
ously described [28]. The loading capacity and encapsulation efficiency 
of doxycycline for bmSF nanospheres were calculated using the 
following formulae (n = 3):  
Loading ​ capacity ​ % ​ = ​ total ​ amount ​ of ​ drug ​ − ​ amount ​ of ​ unbound ​ drug
weight ​ of ​ bmSF ​ nanospheres
× 100%   
Encapsulation ​ efficiency ​ (%) ​ = ​ total ​ amount ​ of ​ drug ​ − ​ amount ​ of ​ unbound ​ drug
total ​ amount ​ of ​ drug
× 100%   
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The weight ratio (doxycycline/SF) of drug added into bmSFsol to 
reach optimum doxycycline encapsulation efficiency was used for 
preparation of drug-loaded nanospheres in all further assays. 
To pre-mix doxycycline with bmSF molecules in bmSFsol (1 wt %), 
doxycycline solution was dropped into bmSFsol to reach a concentration 
(doxycycline/SF) of 3.38% comparable to the drug loading capacity of 
bmSF nanospheres after optimization. The mixture solution was stirred 
at 100 rpm for 24 h before use. 
2.3. Characterization of bmSFsol, apSFsol, and bmSFsus 
To assess the morphology of the bmSF nanospheres, samples were 
freeze-dried at − 52.1C◦ for 3 days (VirTis Benchtop Pro, SP Industries, 
Inc., USA) and examined by scanning electron microscopy (SEM, Sigma- 
300, Zeiss, Germany) after sputtering 10 nm chromium coating. Dy-
namic light scattering (Zetasizer, Nano-S, Malvern Instruments, U.K.) 
was applied to test the ζ-potential of samples (n = 3). The pH of samples 
was measured using a pH meter (PHM210, Hach, U.S.A.). 
2.4. EPD of coatings from bmSFsol+sus and apSFsol 
Pure titanium disks (grade 2, Baoji Titanium Industry, China) were 
used as sample substrates. Grit 600 and Grit 2500 grinding sandpapers 
(Struers, the Netherlands) were used sequentially to smoothen the tita-
nium surface. Subsequently, the titanium disks were washed in acetone, 
ethanol, and water in an ultrasonic bath for 10 min in succession, fol-
lowed by argon plasma treatment (radio-frequency glow discharge 
machine, Harrick, U.S.A.) for 10 min. 
Different amounts of bmSFsol (1 wt %) and bmSFsus (1 wt %) without 
and with drug were mixed together to obtain a series of bmSFsol+sus. The 
total SF concentration was fixed at 1 wt %, while the relative amount of 
nanospheres was varied between 0, 25, 50, 75 and 100%. These 
experimental groups without drug were designated as SFN0, SFN25, 
SFN50, SFN75 and SFN100, respectively, whereas groups with drug 
were designated as SFND0, SFND25, SFND50, SFND75, and SFND100, 
respectively (Table 1). 
To allow for coating deposition using EPD, one titanium disk was 
used as the working positive electrode, and another titanium disk with 
the same size was applied as the counter electrode. The distance be-
tween the two electrodes was set at 1 cm. The EPD process was con-
ducted using a direct current power supply (Model 6614C, Agilent, U.S. 
A.) at a constant electric field of 5 V/cm. The bmSF underlayers were 
first deposited from various types of bmSFsol+sus mixtures. Subsequently, 
these bmSF underlayers were covered by an apSF top-layer by depositing 
apSFsol (1 wt %). For each deposition, a freshly prepared 10 mL 
bmSFsol+sus or apSFsol was used and mildly stirred on a magnetic stirrer 
(50 rpm) during deposition. After deposition, the coated disks were 
gently rinsed with water and slowly air-dried in a box to prevent 
cracking [23]. For drug release and cell culture studies, the coating 
made on the bottom side of disk which touched the box during air drying 
was removed by a Grit 600 grinding sandpaper (Struers, the 
Netherlands). 
2.5. Characterization of the coating system 
SEM was employed to examine the surface topography of the coating 
under-layer and top-layer after coverage by a 10 nm chromium layer. 
Fourier transform infrared spectroscopy (FTIR, Spectrum two with 
the UATR accessory, PerkinElmer, the Netherlands) was used to analyze 
the molecular conformation of the coated bmSF with and without 
doxycycline loading. To calculate the β-sheet and α-helix content of the 
bmSF under-layer with different microstructures, the contribution of the 
different SF conformations to the amide I region (1595-1705 cm-1) was 
determined by Fourier self-deconvolution using PerkinElmer software 
and subsequent curve fitting by OriginPro software according to a pre-
viously reported method (n = 3) [30]. 
A profilometer (Proscan 2100, Scantron Industrial Products, U.K.) 
was used to measure the thickness and roughness of the coatings (n = 3). 
The water contact angle was measured using an Optical Tensiometer 
(Theta Lite, Biolin Scientific, Sweden) to assess the wettability of the 
coating surface (n = 3). 
To determine the degradation kinetics of the coatings, a degradation 
test was performed in PBS solution at a shaking rate of 90 rpm at 37 ◦C 
for 14 days. PBS solution was refreshed every 24 h. At specified time 
points, samples were taken out, gently rinsed with water, dried in an 
oven, and weighted (n = 3). 
A lap shear tensile test was performed to measure the adhesion 
strength, as previously described (Supporting information, Fig. S1a) 
[31]. Briefly, a coated titanium substrate was glued at its coated side to 
an uncoated titanium substrate using an instant epoxy adhesive (Loctite 
415, Loctite, USA). The substrates were vertically fixed on a Universal 
Testing Machine (858 mini bionix II, MTS Systems, U.S.A.). The tensile 
test was carried out using a constant crosshead displacement of 0.50 mm 
per min until failure occurred, as was evidenced by a sudden drop in 
load. The samples (Supporting information, Fig. S1b) were inspected 
using a stereoscopic microscope (MZ12, LEICA, Germany) to ensure that 
failure occurred at the coating-substrate interface rather than the 
coating-adhesive interface. 
2.6. Measurement of drug release profiles from the coating system 
The disks (diameter of 14.5 mm; thickness of 1 mm) with different 
drug loaded coatings were put in 24 well plates and immersed in 1 mL 
PBS solution to ensure the sink conditions were maintained during the 
release test. The plates were sealed with adhesive sealing film (Secure-
Seal, Simport, Canada) and shaken with a rate of 90 rpm at 37 ◦C for 14 
days to perform a drug release study. At specific time points (1 h, 2 h, 4 
h, 8 h, 12 h, 1 d, 2 d, 3 d, 4 d, 7 d, 11 d, 14 d, and 17 d), the supernatant 
was collected and refreshed with new PBS solution. The concentrations 
of doxycycline in collected supernatants were measured using HPLC (n 
= 3). 
We further fitted the drug release data to three commonly-used 
diffusion-controlled models, i.e. the first-order (Equation (1)), Higuchi 
(Equation (2)), Korsmeyer-Peppas (Equation (3)): 
− In(1 − Q)= aT + b (1)  
Q = cT0.5 + d (2)  
Q = kTn (3)  
where Q is the accumulative drug released % at the specific release time 
T; a, b, c, d, n, and k are the constants. 
Table 1 






Total drug concentration 
(doxycycline/bmSF) (w/ 
w %) 
SFN0 0/100 1 0 
SFN25 25/75 1 0 
SFN50 50/50 1 0 
SFN75 75/25 1 0 
SFN100 100/0 1 0 
SFND0 0/100 1 3.38 
SFND25 25/75 1 3.38 
SFND50 50/50 1 3.38 
SFND75 75/25 1 3.38 
SFND100 100/0 1 3.38  
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2.7. Cell culture 
NIH3T3 cells (mouse embryonic fibroblastic cell line) obtained from 
American Type Culture Collection were applied to study the influence of 
apSF top-layer on cell adhesion, spreading and proliferation behavior. 
SFN50 coating was applied as experimental group. We used the coating 
with the same under-layer of SFN50, but a different top-layer deposited 
from bmSFsol instead of apSFsol as the control group, which was desig-
nated as SFN50b (Table 1). The culture medium was Dulbecco’s modi-
fied essential medium (Gibco, Invitrogen, Scotland) supplemented with 
10% calf serum (Gibco, Invitrogen, Scotland) and 1% penicillin/strep-
tomycin. Cells were seeded on UV-light sterilized samples at a density of 
5000 cells⋅cm− 2. 
2.8. Immunofluorescent staining and analysis 
For immunofluorescent observation, cells were fixed at 24 h after cell 
seeding using 4% paraformaldehyde for 10 min. Then, they were 
permeated using 0.1% Triton X-100 for 10 min, and blocked with 1% 
BSA for 1h. To stain the focal adhesions, samples were incubated with 
anti-vinculin primary antibody (1:400, ab129002, Abcam, U.S.A.) at 
4 ◦C overnight, followed by incubation with Alexa-Fluor 647-conjugated 
secondary antibody (1:400, ab150083, Abcam, U.S.A.) at room tem-
perature for 1h. Stained samples were observed using a fluorescence 
microscope (Axio Imager Microscope Z1, Zeiss, Germany). Images 
analysis was performed by Image J (NIH, USA). The quantitative mea-
surement of focal adhesion area per cell followed a step-by-step protocol 
[32]. To label the F-actin, samples were incubated with 
TRITC-phalloidin (1:1000, P1951, Sigma, U.S.A.) for 30 min. Image J 
was used to trace the cell borders to quantify the cell spreading area. At 
least 30 cells were analyzed per group. 
Similarly, to stain Ki-67, a marker of proliferation present during all 
active phases of the cell cycle (G1, S, G2, and mitosis) [19], samples first 
were incubated with anti-Ki67 antibody (1:400, ab16667, Abcam, U.S. 
A.) and then with Alexa-Fluor 594-conjugated secondary antibody 
(1:500, A32740, Abcam, U.S.A.). To label the nucleus, cells were incu-
bated DAPI (1:2000, D9542, Sigma, U.S.A.) for 15 min. The positive 
Ki-67 cell % were calculated based on the images taken from three 
random fields for each sample and three samples were analyzed per 
group (n = 3). 
2.9. Cell adhesion 
After incubating the samples for 2 and 4 h, they were taken out, 
rinsed with PBS to remove any non-adherent cells, and transferred to a 
new plate. The adherent cell number was measured by QuantiFluor 
dsDNA System kit (Promega Corporation, Madison, USA) using spec-
trophotometry according to the manufacturer’s instructions. The cell 
adhesion rate was counted as the ratio between the adherent cell 
number at 2 and 4 h and initial cell seeding number (n = 3). 
2.10. Cell proliferation 
Cell counting kit-8 (CCK-8, Dojindo, Japan) was applied at the spe-
cific time points (1, 3, and 7 d) to measure the total cell number (n = 3). 
The CCK-8 result was tested spectrophotometrically (Bio-Tek FL600 
microplate fluorescence reader, Biotek, U.S.A.) according to the manu-
facturer instructions. 
2.11. Cell cytocompatibility 
After 24h of incubation, Lactate Dehydrogenase (LDH) Assay Kit 
(Thermo Fisher Scientific, U.S.A.) was used for determining cyto-
compatibility of drug-loaded coatings by measuring the LDH activity 
released from damaged cells. cell culture coverslips without and with 
5% DMSO were used as positive and negative controls, respectively, 
while wells added with 2% (v/v) Triton-X100 and only culture medium 
were used as the high and low controls, respectively. The results from 
the LDH assay were tested spectrophotometrically according to the 
manufacturer instructions. Three samples per group were tested. The 
cytocompatibility was calculated using the formula as previously re-
ported [33]: 
Cytocompatibility ​ (%) ​ = ​ (1 −
experimental ​ value − ​ low ​ control
high ​ control − low ​ control
)
× 100%  
2.12. Statistical analysis 
All quantitative data were expressed as mean ± standard deviation 
(SD). Statistical analyses were performed using GraphPad Prism 7.0 
One-way ANOVA followed by Tukey post hoc test was used for multiple 
comparisons. 
3. Results and discussion 
3.1. Electrophoretic assembly mechanism of the coatings 
The spherical morphology of bmSF nanospheres was confirmed by 
SEM (Fig. 1a). The pH of bmSFsus (1 wt %), bmSFsol (1 wt %), and apSFsol 
(1 wt %) was about 7.5, and their ζ-potential values at pH 7.5 were 
− 34.3, − 9.0, − 10.7, respectively (Fig. 1b). The measured ζ-potential 
values were consistent with previous studies [12,34,35], indicating that 
bmSF nanospheres, bmSF molecules, and apSF molecules were all elec-
tronegative. The higher negative charge of bmSF nanoparticles 
compared to bmSF molecules may be due to that the negatively charged 
N-termini are exposed at the surface whereas the positively charged 
C-termini self-assembled inside the nanoparticles at a neutral condition 
[36]. 
Previous work demonstrated that bmSF molecules [11,12,20–22] or 
nanospheres [23] can be electrophoretically deposited onto substrates in 
an aqueous environment. When applying a voltage, negatively charged 
bmSF molecules or nanospheres move towards the anode substrate, 
where water is oxidized, causing pH reduction and neutralizing the 
negative surface charge of bmSF molecules or nanospheres [11,23]. The 
corresponding weakening of repulsive interactions between bmSF mol-
ecules or nanospheres induces their irreversible deposition to form an 
electro-gel on the substrate, which finally transforms into a coating after 
drying [11,23]. 
Here, we chose SFN50 as experimental group to investigate the 
mechanism and kinetics of depositing bmSFsol+sus. The colloidal stability 
of bmSFsol+sus as a function of the pH was studied as compared to the 
bmSFsol or bmSFsus. At pH ≥ 5, the dispersion of the bmSFsol+sus (Fig. 1e), 
similar to the bmSFsol (Fig. 1c) and bmSFsus (Fig. 1d) was stable. How-
ever, when the pH was reduced below 4, flocculation (Fig. 1c) and 
precipitation (Fig. 1d) occurred in solutions and suspensions, respec-
tively, which coincided with the reported pI of bmSF (~4.2) [22]. The 
same phenomena were observed in bmSFsol+sus (Fig. 1e), indicating that 
bmSF molecules and nanospheres in bmSFsol+sus could be co-deposited 
onto the substrate (Fig. 1 a). Moreover, the apSFsol showed the same 
behavior regarding dispersion stability at different pH values as the 
bmSFsol (Fig. 1f v.sc). This is likely due to the comparable pI values of 
apSF (~4.3) [35] and bmSF (~4.2) [22], which indicates that the EPD 
mechanism of apSF molecules is similar to bmSF molecules (Fig. 1 a). 
The key processing parameters determining EPD coating thickness 
have been summarized by Besra, and include the electric field, deposi-
tion time and suspension characteristics [37]. Our previous study 
demonstrated that an electric field of 5V/cm and protein concentration 
of 1.0 wt % enabled deposition of homogeneous coatings from bmSFsol 
[11] or bmSFsus [23]. Therefore, we also applied 5V/cm and 1.0 wt % for 
depositing our coatings. Our data indicated that during deposition of the 
bmSF under-layer, its thickness increased linearly (R2 = 0.993) at 4.5 
X. Cheng et al.                                                                                                                                                                                                                                   
Bioactive Materials 6 (2021) 4243–4254
4247
μm/min when the deposition time increased from 0 to 6 min (Fig. 1g; 
Supporting information, Fig. S2a). Consequently, a moderate time of 2 
min was chosen for under-layer deposition before top-layer deposition. 
The thickness of top-layer increased linearly during deposition at 5.1 
μm/min (R2 = 0.960) with increasing deposition time from 0 to 4 min 
(Fig. 1g; Supporting information, Fig. S2b). 
These results indicate that the EPD process of both layers is Faradaic 
[31], and follows the classical Hamaker equation, which predicts a 
linear increase on deposited mass (thickness) with the increase of 
deposition time at a given electric field and protein concentration [23]. 
However, when the time exceeded 6 min, the increase in coating 
thickness slowed down due to self-limitation. Water was oxidized at the 
interface between substrate surface/electrolyte, whereas deposition 
took place at the interface between the electro-gel surface and electro-
lyte (Fig. 1a). With increasing time, the increasing distance between 
these two interfaces induced the self-limitation phenomena that reduced 
the growth kinetics of the coating [23,31]. 
Fig. 1. EPD process and mechanism of the coating system. (a) Schematic illustration of the coating system involving sequential EPD of a mixture of dissolved 
bmSF molecules and pre-made bmSF nanospheres as under-layer and apSF molecules as top-layer. (b) ζ-potential values. Photos showing colloidal stability of (c) 
bmSFsol, (d) bmSFsus, (e) bmSFsol+sus of SFN 50 group, or (f) apSFsol as a function of pH. (g) Coating thickness of SFN 50 as a function of total deposition time. The apSF 
top-layer is deposited after a 2 min deposition of bmSF under-layer. Error bars represent standard deviations. 
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3.2. Material characterization of the coating system 
Coating deposition times of the under-layer and top-layer were fixed 
at 2 and 1 min, respectively, to study the physicochemical properties of 
coatings with different under-layer architectures (Fig. 2a). The thick-
nesses of these coatings (~13 μm) were comparable (Supporting infor-
mation, Fig. S3). To investigate if the nanosphere concentration in 
bmSFsol+sus correlated with the nanosphere content of under-layer 
Fig. 2. Material characterization of the coating system. (a) SEM images of under-layer and top-layer surfaces of the coating system. (b) FTIR measurement on 
under-layer surfaces showing the absorbance spectra of the amide I region (between 1695 and 1595 cm–1) of bmSF molecules. (c) Conformation contents of bmSF 
molecules calculated by Fourier self-deconvolution from the amide I region spectra. (d) Surface roughness of the coating system. (e) Surface wettability of the coating 
system determined by water contact angle measurements and representative images of water droplets. (f) Remaining mass of coatings immersed in PBS after 1, 3, 7, 
and 14 days. (g) Adhesion strength of the coating system measured by lap shear tensile testing. Error bars represent standard deviations (ns: no significance). 
X. Cheng et al.                                                                                                                                                                                                                                   
Bioactive Materials 6 (2021) 4243–4254
4249
architectures, SEM and FTIR were used to examine the bmSF under-layer 
surface without depositing an apSF top-layer. 
With increasing nanosphere concentration, SEM images showed that 
the underlayer surface became more irregular, as more bmSF nano-
spheres were observed embedded in the coating architectures (Fig. 2a). 
The SF conformation of different coatings was calculated by Fourier self- 
deconvolution from the spectra of the amide I region as measured by 
FTIR (Fig. 2b and c). Previous work indicated that deposition of bmSFsol 
induced an obvious conformational transformation from random-coil to 
α-helical state of bmSF [21]. In contrast, the formation of bmSF nano-
spheres led to a large amount of β-sheet conformation [34], which was 
not affected by the EPD process [23]. With increasing nanosphere con-
centration, the β-sheet and α-helical contents in deposited coatings lin-
early increased (R2 = 0.967) and decreased (R2 = 0.955), respectively 
(Fig. 2c; Supporting information, Fig. S4). These results indicate that the 
nanosphere content of the under-layer architectures correlates linearly 
with the nanosphere concentration in bmSFsol+sus. 
Subsequently, we characterized the top-layer of coatings. SEM im-
ages showed that the application of apSF top-layers flattened the un-
derlying under-layers (Fig. 2a), resulting in a comparable surface 
roughness (Fig. 2d). The water contact angles did not differ significantly 
among the various experimental groups (Fig. 2e), since the chemical 
composition and surface topography of the top-layer were similar [38, 
39]. The smooth surface and moderate hydrophobicity of our coatings 
were similar to percutaneous parts of commercially available titanium 
implants [39]. 
The deposited coatings showed very limited degradation within 14 
days (Fig. 2f), which was in line with a previous study on SF-based 
materials [23]. The adhesion strength between coating system and 
substrate was investigated in a lap shear tensile test (Fig. 2g and Fig. S1, 
Supporting information). The various under-layers adhered equally 
strong to the substrate. The adhesion strength (3.6–5.4 MPa) of the 
coating system was similar to the strength of other reported 
EPD-deposited polymer-based coatings (1.5–8 MPa) [10–12,16,40], but 
lower than the adhesion strength of bmSF coatings observed previously 
(6.7–8.2 MPa) [23]. This reduced adhesion strength can be attributed to 
increased coating thickness caused by the double-layer design. Howev-
er, the adhesion strength of our coating system is sufficient for devices 
that are not subjected to high shear and tensile forces, such as the 
transcutaneous part of percutaneous implants [17]. 
Fig. 3. apSF top-layer improves initial cell 
response of the coatings. (a) Cell spreading at 24 
h shown by immunofluorescent images of vinculin 
(purple), F-actin (grey), and nucleus (blue), as well 
as the corresponding heatmap of F-actin. (b) 
Adherent cell ratio of cells cultured on different 
surfaces at 2 and 4 h measured by DNA content 
assay. (c) Quantitative analysis of focal adhesion 
area per cell. (d) Quantitative analysis of cell area. 
(e) Cell proliferating phase at 24h shown as 
immunofluorescent images of nucleus (blue) and Ki- 
67 protein (red). (f) Quantitative analysis of the 
positive ki-67 cells %. (g) Cell number at 1, 3, and 7 
d measured by CCK-8. Error bars represent standard 
deviations (*: p < 0.05 and **: p < 0.01). (For 
interpretation of the references to colour in this 
figure legend, the reader is referred to the Web 
version of this article.)   
X. Cheng et al.                                                                                                                                                                                                                                   
Bioactive Materials 6 (2021) 4243–4254
4250
3.3. apSF top-layer improves initial cell response of the coatings 
To evaluate the effect of apSF top-layer on cell behavior, initial cell 
response including adhesion, spreading and proliferation was assessed 
for different material surfaces, i.e. apSF top-layer, bmSF top-layer and 
uncoated substrate (Fig. 3a). Before seeding cells, the samples were 
sterilized by UV-light in this study. However, other routine sterilization 
methods, such as gamma irradiation, can also be used to sterilize SF 
materials [41] and loaded doxycycline [42]. 
After 2 h of cell seeding, the adherent cell ratio was higher on apSF 
top-layer than on bmSF top-layer (p < 0.01) and uncoated titanium 
substrate (p < 0.05) (Fig. 3b). After 4 h, the number of adherent cells 
increased for all different material surfaces, but the adherent cell ratio 
on bmSF top-layer was still significantly lower than on apSF top-layer (p 
< 0.05) (Fig. 3b). This result indicates that an apSF top-layer accelerates 
the cell adhesion process as compared to bmSF top-layer and titanium 
substrate. The faster cell adhesion on a material surface with a high 
content of RGD sequences has also been observed elsewhere [19,43,44]. 
Furthermore, a previous study found that the incorporation of recom-
binant RGD motif-containing peptides derived from apSF into bmSF 
films was even more effective for rapid cell adhesion of L929 cells 
(another murine fibroblast cell line) than incorporation of chemically 
synthesized RGD peptides [43]. 
After 24 h, cells accomplished their adhesion and spreading process 
[19]. The immunostaining images of F-actin and subsequent analysis 
show that cells on apSF top-layer spread over a larger area (Fig. 3a and 
d) (p < 0.01) with more abundant cytoskeleton organization (Fig. 3a) 
than cells on the other substrates. The immunostaining images of 
Fig. 4. Drug loading and release of the coating system. (a) Schematic illustration of the process of drug loading onto the coatings. Model drug, doxycycline, was 
either pre-mixed with dissolved bmSF molecules or pre-loaded into pre-made bmSF nanospheres before under-layer deposition. (b) Encapsulation efficiency of bmSF 
nanospheres as a function of the weight ratio (drug/protein). (c) ζ-potential values of drug-loaded bmSF nanospheres and molecules. (d) FTIR measurement on pure 
doxycycline powder, underlayer surface of SFN50 and underlayer surface of SFND50. Drug release profiles of the coating system shown as the (e) cumulative release 
amount or (f) cumulative release percentage of the maximum release amount using different nanosphere concentrations and the same under-layer deposition time (2 
min). (g) Drug release profiles of SFND50 group for different under-layer deposition times at a fixed nanosphere concentration (50%). Error bars represent stan-
dard deviations. 
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vinculin and subsequent corresponding analysis (Fig. 3a and c) display 
that more vinculin-associated focal adhesions were formed in cells on 
apSF top-layer as compared to those on bmSF top-layer and titanium 
substrate (p < 0.05). Previous studies also reported that a high content 
of RGD sequences in materials upregulated vinculin expression and 
facilitated focal adhesion formation [19,45], which coincides with our 
results. Via linking F-actin to the vinculin at focal adhesion, vinculin can 
trigger a series of phosphorylation events to promote cytoskeleton or-
ganization and cell spreading [46]. 
To study proliferation during the cell cycle, Ki-67 was stained after 
24 h of cell culture. Ki-67 is a marker of proliferation present during all 
active phases of the cell cycle (G1, S, G2, and mitosis) [19]. Our results 
(Fig. 3e and f) showed that the proportion of Ki-67 positive cells on apSF 
top-layer was higher than on bmSF top-layer (p < 0.01) and uncoated 
titanium substrates (p < 0.05). This indicates that the apSF top-layer 
stimulated more cells to enter the active phases of the cell cycle for 
proliferation (i.e. proliferative phase). Subsequently, CCK-8 tests were 
performed to evaluate cell growth from 1 to 7 days (Fig. 3g). A signifi-
cantly higher number of cells was observed at all time points on top of 
apSF top-layer as compared to other experimental groups. This obser-
vation can be attributed to the faster cell adhesion, better cell spreading 
and higher proportion of cells entering the proliferative phase on apSF 
surface as compared with the other material surfaces. Additionally, a 
slightly lower proliferative activity of cells was observed on SFN50b as 
compared to uncoated titanium substrate although there was no statistic 
significance. This may be attributed to the relatively weak cell adhesion 
to bmSF due to the absence of cell recognition motifs and its negatively 
charged nature [47]. 
3.4. Tunable drug delivery of the coating system 
The model drug doxycycline was either pre-loaded into bmSF 
nanospheres in bmSFsus and pre-mixed with bmSF molecules in bmSFsol 
at the same amount before their mixing and deposition (Fig. 4a). The 
optimum weight ratio (doxycycline/SF) of doxycycline added into 
bmSFsol when preparing drug loaded bmSF nanospheres was 0.15, where 
the maximum drug encapsulation efficiency was 22.5 ± 1.3% (Fig. 4b) 
and the loading content was 3.38 ± 0.19%. Compared to the encapsu-
lation efficiency of some lipophilic drugs, e.g. curcumin (48 ± 2.7%), the 
one of doxycycline was relatively low [48]. This indicates that part of 
the water-soluble doxycycline stayed in the aqueous phase and could not 
co-precipitate with SF. Also, the washing steps may lead to drug loss. 
Future studies should be done to improve the drug encapsulation 
efficiency. 
Drug loading decreased the negative surface charge of nanospheres 
from − 34.3 to − 25.7 mV (Figs. 1b and 4c). This phenomenon results 
from partial neutralization of negatively charged bmSF nanospheres by 
positively charged doxycycline [34], and indicates that electrostatic 
interactions may form between the doxycycline and bmSF [17]. On the 
other hand, the zeta potential value of bmSFsol decreased from − 9.0 to 
− 5.1 mV after pre-mixing drug with bmSF molecules in bmSFsol (Figs. 1b 
and 4c), indicating that polyelectrolyte complex may form between 
doxycycline and bmSF molecules [12]. 
FTIR was performed on the under-layer surface without a top-layer 
(SFND50 as an example group) (Fig. 4d). The SFND50 coating 
possessed three typical absorbance peaks at 1619 cm− 1 (amide I band), 
1512 cm− 1 (amide II band), and 1230 cm− 1 (amide III band) for silk 
protein [30]. Extra absorbance peaks at 1309 and 1130 cm− 1 for 
doxycycline [28] were also found in the spectrum of the SFND50 coating 
as compared to the SFN50 coating without drug, indicating successful 
loading of doxycycline. 
HPLC was applied to monitor drug release profiles from the coating 
system. After the first 12 h, all formulations of the coating system dis-
played an initial burst release, even though the burst release rate was 
reduced from 87 to 27 % by increasing the nanosphere concentration 
from 0 to 100 % (Supporting information, Fig. S6). For antibiotic release 
coatings, an initial burst release of high concentration of antibiotics is 
generally considered required to eradicate bacterial contamination upon 
surgery, whereas a long-term sustained local release of antibiotics can 
prevent bacterial re-colonization on implant surfaces [14,17,29]. Our 
and other studies have demonstrated that antibiotics released from bmSF 
molecule EPD coating [12] or bmSF nanosphere EPD coating [23] can 
retain their drug effectiveness. These findings point to a stabilizing effect 
of bmSF molecules on sensitive biological compounds (e.g. antibiotics) 
upon incorporation into bmSF matrices [24]. Besides, the drug-loaded 
coating (SFND50 as an example group) was not cytotoxic to fibro-
blasts (Supporting information, Fig. S7). 
Applying the same under-layer deposition time (2 min), both the 
duration (Fig. 4f) and amount of drug release (Fig. 4e) increased with 
increasing nanosphere concentration. Our previous study demonstrated 
that the usage of pre-made bmSF nanospheres as coating building blocks 
instead of dissolved bmSF molecules remarkably increased the amount 
and duration of electropositive antibiotics (e.g. vancomycin) by estab-
lishing strong electrostatic and hydrophobic interactions between the 
drug and nanospheres [23]. Therefore, in the current study, bmSF 
nanospheres in the under-layer increased the loading capacity and 
reduced diffusion of encapsulated drugs as compared to their sur-
rounding bmSF matrix. Consequently, the gradual increase in drug 
release duration and amount with increasing nanosphere concentration 
in bmSFsol+sus was attributed to the higher content of nanospheres in 
under-layer architectures. Additionally, using the same nanosphere 
concentration (50%), the drug release dosage from the coating system 
increased with increased deposition time of the under-layer from 1 to 4 
min (Fig. 4g). 
We further examined the relationship between processing parame-
ters and drug release kinetics by fitting release data to three commonly 
used release models (i.e. the first-order, Higuchi, and Korsmeyer- 
Peppas) (Fig. 5a–c). The coefficients of determination (R2) of these fit-
tings were all higher than 0.92, indicating that release data fitted well 
with all three models. The first-order and Higuchi model are diffusion- 
controlled release models [49], indicating that the release kinetics of 
coating system followed a diffusion-controlled manner. Moreover, the 
values of n in Korsmeyer-Peppas also indicate the specific drug release 
mechanisms [50]. With increase of nanosphere concentration from 25 to 
100%, the values of n increased from 0.078 to 0.294. All values were 
below the crucial value 0.45, confirming that drug were released from 
the coating system according to a typical Fickian diffusion process [50]. 
The increase of n indicated that the increase of nanosphere content in 
the under-layer architecture delayed this diffusion process [50]. 
Furthermore, we found that all model constants displayed simple 
linear relationships (R2 = 0.90–0.99) with nanosphere concentration in 
bmSFsol+sus (Fig. 5d–f), indicating that our coating system allows for 
prediction of release kinetics by tuning nanosphere concentrations. 
Additionally, a linear relationship (R2 = 0.89) was observed between 
nanosphere concentrations and release durations (90% maximum 
release) (Fig. 5g). This result confirms that the required drug release 
duration can be tuned for specific applications by adjusting the nano-
sphere concentration before coating preparation (Fig. 5j). On the other 
hand, the maximum drug release amount increased linearly with 
nanosphere concentration at the same deposition time (i.e. 2 min) 
(Fig. 5h), and was proportional to the under-layer deposition time using 
the same nanosphere concentration (i.e. SFN50) (Fig. 5i). This may be 
ascribed to the linear relationship between thickness of the under-layer 
and deposition time before reaching self-limitation (Fig. 1g). This result 
indicates that the deposition time can be used a tool to achieve the 
desired drug release dosage for a specific application (Fig. 5j). 
Although promising results have been acquired only on using SF as 
coating matrix here, other commonly-used EPD coating matrix materials 
such as chitosan, alginate, and ceramics have also been widely used to 
assemble different nano- or micro-carriers for sustained therapeutic 
drug release [51–53]. Therefore, we envision that pre-defined archi-
tecture EPD strategy may be also be applied to those materials to achieve 
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Fig. 5. Relationships between processing parameters and drug release kinetics of the coating system. Release model fits of (a, d) first-order, (b, e) Higuchi, 
and (c, f) Korsmeyer-Peppas equations. Relationships between the constants in (g) first-order, (h) Higuchi, and (i) Korsmeyer-Peppas models and nanosphere 
concentration in EPD suspensions (N). (g) Relationship between the release time (90% maximum release) (i.e. “T”) and N. (i) Relationship between the maximum 
release amount (i.e. “M”) and N using the same under-layer deposition time (i.e. “t”) (2 min). (h) Relationship between M and t using the same N (50%). (j) 
Schematic illustrating that drug release duration and dosage of the coating system can be quantitatively tailored by manipulating processing parameters N and t. 
Moreover, the apSF top-layer design enhances cytocompatibility of the coatings. 
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tunable drug delivery coating system. As for the developments of a 
medical applicable coating system, conversion to dosage forms, 
enhancement on drug loading efficiency, as well as pharmaceutical ac-
tivity and release dynamics in different physiological stimuli (e.g., pH 
and anions) or in vivo conditions deserve further investigation. 
4. Conclusions 
A novel double-layered SF coating system was designed by sequen-
tial EPD of a mixture of both dissolved bmSF molecules and pre-made 
bmSF nanospheres at tunable ratios as under-layer covered by apSF 
molecules as top-layer to improve the control over drug delivery and the 
response of adherent cells. The model drug doxycycline was either pre- 
mixed with dissolved bmSF molecules or pre-loaded into pre-made bmSF 
nanospheres before deposition of the under-layers. The thickness and 
nanosphere content of the under-layers were controlled by the deposi-
tion time and nanosphere concentration in mixture precursors, respec-
tively. The apSF top-layer increased adhesion, spreading, and 
proliferation of fibroblasts as compared with bmSF top-layer and non- 
coated titanium substrates. Moreover, drug release amount and dura-
tion linearly increased with nanosphere concentration using the same 
deposition time. Furthermore, at a given nanosphere concentration, the 
increase of deposition time also enabled a linear enhancement on drug 
release amount. These results indicate that the drug release dosage and 
duration can by precisely controlled by altering two key processing 
parameters (nanosphere concentration in mixture precursors and 
deposition time). Overall, this study illustrates the strong potential of 
pre-defining the architecture of coatings to facilitate precise control over 
drug delivery. 
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